PRA Health Sciences Stock Price, News & Analysis (NASDAQ:PRAH)

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

PRA Health Sciences Inc (NASDAQ:PRAH) issued its quarterly earnings data on Wednesday, July, 31st. The medical research company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of $1.11 by $0.11. The medical research company had revenue of $763.31 million for the quarter, compared to analyst estimates of $764.95 million. PRA Health Sciences had a net margin of 5.39% and a return on equity of 26.64%. The firm's revenue was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.00 EPS. View PRA Health Sciences' Earnings History.

PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for PRA Health Sciences.

PRA Health Sciences will be holding an earnings conference call on Wednesday, October 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

PRA Health Sciences issued an update on its FY 2019 earnings guidance on Wednesday, July, 31st. The company provided earnings per share (EPS) guidance of $4.98-5.08 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.01. The company issued revenue guidance of $3.02-3.1 billion, compared to the consensus revenue estimate of $3.1 billion.

9 Wall Street analysts have issued 1-year target prices for PRA Health Sciences' stock. Their predictions range from $100.00 to $126.00. On average, they expect PRA Health Sciences' stock price to reach $115.86 in the next year. This suggests a possible upside of 17.6% from the stock's current price. View Analyst Price Targets for PRA Health Sciences.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PRA Health Sciences.

News articles about PRAH stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. PRA Health Sciences earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave news stories about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for PRA Health Sciences.

Some companies that are related to PRA Health Sciences include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), Auxly Cannabis Group (CBWTF), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE), Luna Innovations (LUNA) and Pieris Pharmaceuticals (PIRS).

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Adobe (ADBE), Applied Materials (AMAT), Paypal (PYPL), Lam Research (LRCX), Veeva Systems (VEEV), Netflix (NFLX), Splunk (SPLK) and GrubHub (GRUB).

(PRAH) raised $306 million in an initial public offering (IPO) on Thursday, November 13th 2014. The company issued 17,000,000 shares at a price of $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

PRA Health Sciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Stephens Investment Management Group LLC (0.69%), Artemis Investment Management LLP (0.36%), CIBC Private Wealth Group LLC (0.26%), Scout Investments Inc. (0.14%), Reilly Financial Advisors LLC (0.13%) and Pacer Advisors Inc. (0.03%). Company insiders that own PRA Health Sciences stock include David W Dockhorn, Fund Holdings LP Kkr, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.

PRAH stock was sold by a variety of institutional investors in the last quarter, including Bowling Portfolio Management LLC, Scout Investments Inc., Campbell & CO Investment Adviser LLC, Pacer Advisors Inc., CIBC Private Wealth Group LLC and Nisa Investment Advisors LLC. View Insider Buying and Selling for PRA Health Sciences.

PRAH stock was acquired by a variety of institutional investors in the last quarter, including Reilly Financial Advisors LLC, Artemis Investment Management LLP, Stephens Investment Management Group LLC, Fox Run Management L.L.C., State of Alaska Department of Revenue, Toth Financial Advisory Corp, Envestnet Asset Management Inc. and Meeder Asset Management Inc.. View Insider Buying and Selling for PRA Health Sciences.

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PRAH stock can currently be purchased for approximately $98.49.

PRA Health Sciences has a market capitalization of $6.49 billion and generates $2.87 billion in revenue each year. The medical research company earns $153.90 million in net income (profit) each year or $3.93 on an earnings per share basis. PRA Health Sciences employs 16,400 workers across the globe.View Additional Information About PRA Health Sciences.

The official website for PRA Health Sciences is http://www.prahs.com/.

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]